HC Wainwright Reiterates “Buy” Rating for Alto Neuroscience (NYSE:ANRO)

Alto Neuroscience (NYSE:ANRO)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a report released on Monday,Benzinga reports. They presently have a $50.00 price target on the stock. HC Wainwright’s target price points to a potential upside of 97.15% from the stock’s previous close.

A number of other research analysts have also commented on the stock. JonesTrading dropped their price objective on shares of Alto Neuroscience from $49.00 to $44.00 and set a “buy” rating on the stock in a research note on Thursday, April 2nd. Jefferies Financial Group reissued a “buy” rating and set a $35.00 price target on shares of Alto Neuroscience in a report on Monday, March 16th. Bank of America began coverage on Alto Neuroscience in a research note on Tuesday, May 5th. They set a “buy” rating and a $35.00 price objective for the company. Wall Street Zen raised Alto Neuroscience from a “sell” rating to a “hold” rating in a report on Saturday. Finally, BTIG Research upped their price target on Alto Neuroscience from $27.00 to $28.00 and gave the stock a “buy” rating in a research note on Tuesday, February 17th. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $35.13.

Alto Neuroscience Stock Performance

NYSE ANRO traded up $1.10 on Monday, reaching $25.36. The stock had a trading volume of 159,675 shares, compared to its average volume of 269,323. The stock has a market cap of $810.18 million, a P/E ratio of -11.65 and a beta of 1.62. Alto Neuroscience has a 12-month low of $2.15 and a 12-month high of $28.44. The business’s 50-day moving average price is $22.78 and its 200 day moving average price is $18.00. The company has a debt-to-equity ratio of 0.12, a quick ratio of 15.69 and a current ratio of 15.69.

Alto Neuroscience (NYSE:ANRO) last announced its earnings results on Monday, March 16th. The company reported ($0.45) EPS for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.11. As a group, equities analysts expect that Alto Neuroscience will post -2.47 earnings per share for the current year.

Institutional Trading of Alto Neuroscience

Several hedge funds have recently modified their holdings of ANRO. Commodore Capital LP acquired a new stake in Alto Neuroscience in the fourth quarter valued at $32,453,000. Perceptive Advisors LLC lifted its stake in shares of Alto Neuroscience by 1,048.5% in the fourth quarter. Perceptive Advisors LLC now owns 1,784,393 shares of the company’s stock valued at $31,762,000 after purchasing an additional 1,629,027 shares during the period. Vestal Point Capital LP boosted its holdings in Alto Neuroscience by 161.6% during the fourth quarter. Vestal Point Capital LP now owns 2,485,000 shares of the company’s stock worth $44,233,000 after buying an additional 1,535,000 shares in the last quarter. Vivo Capital LLC purchased a new stake in Alto Neuroscience during the fourth quarter worth about $18,433,000. Finally, Ikarian Capital LLC grew its position in Alto Neuroscience by 368.2% during the fourth quarter. Ikarian Capital LLC now owns 515,000 shares of the company’s stock worth $9,167,000 after buying an additional 405,000 shares during the period.

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.